Home
VBI Vaccines

VBI Vaccines Market Share Analysis for May 2026

Variation Biotechnologies Inc., also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel.

Health > Biotechnology and Pharmaceuticals

Domainvbivaccines.com

Year Founded2001

Employees51 - 200

Annual Revenue< $1M

VBI Vaccines

VBI Vaccines (including company regionals)

vbivaccines.com

See more website traffic and engagement information

Total visits to VBI Vaccines's top domains

Understand VBI Vaccines market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

vbivaccines.com4.7K

See more with Sales Intelligence

Avg. visit duration in VBI Vaccines's top domains

Analyze VBI Vaccines engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

vbivaccines.com00:00:28

See more with Sales Intelligence

Avg. pageviews on VBI Vaccines's top domains

See how VBI Vaccines keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

vbivaccines.com1.55

See more with Sales Intelligence

VBI Vaccines top competitors by domain

Top similar sites in May 2026, ranked by their affinity

dynavax.comCompany NameDynavax TechnologiesEmployees201 - 500HQUnited States, California, EmeryvilleAnnual revenue$200M - $500MTotal visits5.4KHealth > Biotechnology and Pharmaceuticals

Top technologies used by VBI Vaccines

These are the website technologies, by industry, used by VBI Vaccines top domains

Advertising (4)

Google Adsense

Audio Video Media (4)

YouTube

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

More Technologies

9

See all

News & Signals from VBI Vaccines

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVBI Vaccines Inc. is developing In Vivo Nanoparticle technologies.Vaccine Company is developing proprietary In Vivo Nanoparticle (IVN) technologies designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production.

NewsVBI Vaccines Inc. launched interim tumor response data on May 29th '24.CAMBRIDGE, Mass.-(BUSINESS WIRE)-VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.

NewsVBI Vaccines Inc. received financing of $2.5M on Jun 30th '24.VBI received $2.5 million of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5 million of consideration, subject to achievement of certain activities, with a target completion date of June 30, 2024.